Johnson & Johnson Total Common and Preferred Stock Dividends Paid 2010-2024 | JNJ

Johnson & Johnson annual/quarterly total common and preferred stock dividends paid history and growth rate from 2010 to 2024. Total common and preferred stock dividends paid can be defined as the cash outflow for all company dividends paid out to preferred and common shareholders.
  • Johnson & Johnson total common and preferred stock dividends paid for the quarter ending September 30, 2024 were $-8.839B, a 0.74% decline year-over-year.
  • Johnson & Johnson total common and preferred stock dividends paid for the twelve months ending September 30, 2024 were $-29.332B, a 0.78% decline year-over-year.
  • Johnson & Johnson annual total common and preferred stock dividends paid for 2023 were $-11.77B, a 0.75% increase from 2022.
  • Johnson & Johnson annual total common and preferred stock dividends paid for 2022 were $-11.682B, a 5.89% increase from 2021.
  • Johnson & Johnson annual total common and preferred stock dividends paid for 2021 were $-11.032B, a 5.26% increase from 2020.
Johnson & Johnson Annual Total Common and Preferred Stock Dividends Paid
(Millions of US $)
2023 $-11,770
2022 $-11,682
2021 $-11,032
2020 $-10,481
2019 $-9,917
2018 $-9,494
2017 $-8,943
2016 $-8,621
2015 $-8,173
2014 $-7,768
2013 $-7,286
2012 $-6,614
2011 $-6,156
2010 $-5,804
2009 $-5,327
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $373.591B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $710.098B 73.55
Novo Nordisk (NVO) Denmark $471.460B 34.00
AbbVie (ABBV) United States $312.696B 16.46
Merck (MRK) United States $250.889B 16.67
Novartis AG (NVS) Switzerland $213.148B 14.17
AstraZeneca (AZN) United Kingdom $203.493B 17.32
Pfizer (PFE) United States $145.358B 9.94
Sanofi (SNY) $122.526B 11.10
Innoviva (INVA) United States $1.199B 9.97